Ellenbecker Investment Group Invests $212,000 in Pfizer Inc. (NYSE:PFE)


Share on StockTwits

Ellenbecker Investment Group bought a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 5,767 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

Several other large investors also recently bought and sold shares of PFE. NuWave Investment Management LLC lifted its position in shares of Pfizer by 439.7% in the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,196 shares during the period. Dimension Capital Management LLC purchased a new stake in shares of Pfizer in the 3rd quarter worth about $58,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Pfizer in the 3rd quarter worth about $59,000. Demars Financial Group LLC purchased a new stake in shares of Pfizer in the 2nd quarter worth about $75,000. Finally, RMR Wealth Builders purchased a new stake in shares of Pfizer in the 2nd quarter worth about $91,000. 69.08% of the stock is owned by hedge funds and other institutional investors.

Pfizer stock traded down $0.32 during trading hours on Wednesday, hitting $36.86. The stock had a trading volume of 881,404 shares, compared to its average volume of 36,397,031. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $204.88 billion, a P/E ratio of 14.60, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $43.08. The stock’s 50-day moving average price is $38.24 and its 200-day moving average price is $37.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $12.13 billion during the quarter, compared to analyst estimates of $12.30 billion. During the same period in the previous year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be paid a $0.39 dividend. The ex-dividend date is Thursday, January 28th. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s payout ratio is currently 51.53%.

PFE has been the subject of several research analyst reports. Royal Bank of Canada set a $42.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, January 4th. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, November 9th. Truist initiated coverage on shares of Pfizer in a research report on Friday, October 23rd. They set a “buy” rating and a $42.00 price target for the company. Berenberg Bank initiated coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price target for the company. Finally, SVB Leerink lifted their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, October 28th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $39.87.

In related news, major shareholder Pfizer Inc purchased 1,200,000 shares of Pfizer stock in a transaction dated Tuesday, October 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $12,000,000.00. Following the completion of the purchase, the insider now directly owns 27,349,211 shares of the company’s stock, valued at approximately $273,492,110. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.08% of the company’s stock.

Pfizer Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Read More: Circuit Breakers

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.